Celularity announced that the company received notification from the Listing Qualifications department of Nasdaq stating that because the company has not yet filed its Form 10-Q for the quarter ended June 30 and because the company remains delinquent in filing its Form 10-Q for the quarter ended June 30, it does not comply with the Nasdaq continued listing requirements which require listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on Nasdaq.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELU:
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
- Celularity Board Member Marc Mazur Announces Resignation
- Celularity sees Q2 net sales of biomaterial product, biobanking $11M-$13M
- Celularity sees Q1 net sales of biomaterial product, biobanking $14.8M
- Celularity reports Q4 combined net sales $12.1M